Quad Cities Investment Group LLC Buys 4,146 Shares of Organon & Co. (NYSE:OGN)

Quad Cities Investment Group LLC lifted its position in Organon & Co. (NYSE:OGN) by 37.5% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 15,211 shares of the company’s stock after purchasing an additional 4,146 shares during the period. Quad Cities Investment Group LLC’s holdings in Organon & Co. were worth $227,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Weiss Asset Management LP purchased a new stake in Organon & Co. in the 3rd quarter worth approximately $32,966,000. AQR Capital Management LLC raised its position in shares of Organon & Co. by 39.8% in the second quarter. AQR Capital Management LLC now owns 3,473,655 shares of the company’s stock worth $71,905,000 after buying an additional 988,336 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its position in shares of Organon & Co. by 303.8% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,242,135 shares of the company’s stock worth $23,762,000 after buying an additional 934,505 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Organon & Co. by 35.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 3,323,051 shares of the company’s stock valued at $63,570,000 after buying an additional 875,128 shares during the period. Finally, Philip James Wealth Mangement LLC purchased a new position in Organon & Co. during the third quarter worth about $15,386,000. 77.43% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Evercore ISI raised Organon & Co. to a “strong-buy” rating in a report on Wednesday, September 18th.

Organon & Co. Stock Performance

NYSE OGN opened at $15.63 on Tuesday. Organon & Co. has a 52-week low of $13.87 and a 52-week high of $23.10. The company has a fifty day moving average of $15.34 and a 200-day moving average of $18.34. The company has a market capitalization of $4.03 billion, a P/E ratio of 3.10, a P/E/G ratio of 0.81 and a beta of 0.76. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.03). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The firm had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. During the same period last year, the firm earned $0.78 EPS. The company’s revenue for the quarter was up 4.1% on a year-over-year basis. As a group, equities research analysts predict that Organon & Co. will post 3.89 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, December 12th. Shareholders of record on Tuesday, November 12th were paid a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 7.17%. The ex-dividend date was Tuesday, November 12th. Organon & Co.’s dividend payout ratio is currently 22.22%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.